When Opportunity Knocks: Eisai Turns To Business Development
Executive Summary
Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer – with an emphasis on externally sourced innovation – that put aggressive business development front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise.
You may also be interested in...
CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.
AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013
Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.
Affymax Considers Bankruptcy As Omontys Investigation Continues
Affymax cuts staff in order to conserve the little cash it has left in its coffers, which will be needed to pay down debts and continue looking into safety issues surrounding its sole commercial product – an investigation that may never be concluded because the company lacks resources.